Launch of Subcutaneous Injection formulation, Actemra

The Company's Official Page
http://www.chugai-pharm.co.jp/hc/ss/english/news/detail/20130524113000.html
Back To Previous Page

Translation

May 24, 2013

Launch of Subcutaneous Injection formulation, Actemra®,
for a Treatment of Rheumatoid Arthritis
The First Anti-IL-6 Receptor Antibody in Subcutaneous market

May 24, 2013 - Chugai Pharmaceutical Co., Ltd. [Main Office: Chuo-ku, Tokyo. Chairman & CEO: Osamu Nagayama] (hereafter, “Chugai”)] announced today that it launched the subcutaneous injection formulation of the humanized anti-human interleukin-6 (IL-6) receptor monoclonal antibody (tocilizumab; genetical recombination), “Actemra®162mg Syringe for SC Injection and Actemra®162mg Auto-Injector for SC Injection”, as the indication of “rheumatoid arthritis that does not respond sufficiently to one or more existing therapies (including inhibition of structural joint damage)” on May 24, 2013


Latest News: Pharmaceuticals

    この内容でのリリース掲載はまだ無いか、集計されておりません。

    この内容でのリリース掲載はまだ無いか、集計されておりません。

Most Popular: Pharmaceuticals

1. Press Release relating to FDA Approval f...
Hisamitsu Pharmaceutical Co., Inc. 2008/02/22
2. Hisamitsu Announces U.S. Launch of its &...
Hisamitsu Pharmaceutical Co., Inc. 2010/03/25
3. Phase II study results of HOB-294 (trans...
Hisamitsu Pharmaceutical Co., Inc. 2009/08/06
4. Notice Regarding Worldwide Patent and Kn...
Mitsubishi Tanabe Pharma Corporation 2015/09/17
5. Announcement of FY2015 2nd Quarter Finan...
Mitsubishi Tanabe Pharma Corporation 2015/10/30

Latest News: Chugai Pharmaceutical Co., Ltd.


Most Popular: Chugai Pharmaceutical Co., Ltd.

1. Chugai Presents"Volunteer for Life:...
2009/11/11

Categories

Go to Page Top

View: Smartphone | PC

Language: English | Japanese

Home

Terms & Conditions

TwitterFacebook

About Us